COVID-19 and the Heart, Experience from Front Line

COVID-19 is a fast-moving pandemic. The infection has a mortality rate of 3-6%. Patients with underlying CVD are at higher risk of contracting COVID-19 and have a worse prognosis.
Our experts from Wuhan China and Singapore have shared clinical experiences from frontline China on management of COVID-19 patients with underlying heart disease.

Topics include:

1. Diagnosis to management of COVID-19 patients with underlying CVD: Learnings from China
2. COVID-19 and Anti-hypertensive Drugs
3. Clinical Case sharing – experience from Singapore

Professor Zhou Ning – Clinical Characteristics and Management of COVID-19 Patients

Professor Koji Hasegawa – COVID-19 and Anti-hypertensive Drugs

Dr Ling Li Min – Clinical Case Sharing – Experiences from Singapore

Panel Discussion